An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
Sponsor: Bayer
A PHASE3 clinical study on Acute Coronary Syndrome and Myocardial Infarction, this trial is completed. The trial is conducted by Bayer and has accumulated 10 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Nov 2025 — Mar 2026 [monthly]
Completed PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Afula, Israel , Aguascalientes, Mexico , Ahmedabad, India , Alexandria, Egypt , Alicante, Spain , Allahabād, India , Amarillo, United States , Amsterdam, Netherlands , Anaheim, United States and 544 more locations